|Dr. Howard J. Federoff M.D., Ph.D.||CEO, Pres & Director||608.81k||N/A||1954|
|Dr. Kevin A. D'Amour Ph.D.||Chief Scientific Officer||448.62k||N/A||1973|
|Dr. Roger Sidhu M.D.||Chief Medical Officer||501.95k||N/A||1976|
|Ms. Sandra M. Gurrola||VP of Fin.||N/A||N/A||1967|
|Dr. Monil Shah M.B.A., Pharm.D.||Chief Operating Officer||N/A||N/A||N/A|
|Mr. Jay Sial||Chief Admin. Officer||N/A||N/A||1965|
|Ms. Lynn Sadowski Mason M.S.||Exec. VP of Clinical Operations||N/A||N/A||1979|
|Ms. Susan McClatchey||VP & Head of Quality||N/A||N/A||N/A|
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Brooklyn ImmunoTherapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 7. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 7; Compensation: 7.